C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - Pipeline Review, H2 2018
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) - C-C chemokine receptor type 4 is a protein encoded by the CCR4 gene. CCR4 is expressed on Th2 T lymphocytes and is up-regulated by T cell receptor activation. This receptor also plays an important role in trafficking of dendritic cells. The CC chemokines CCL3, CCL5, CCL17 and CCL22 signal through this receptor.
C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Central Nervous System, Dermatology, Immunology and Respiratory which include indications Gastric Cancer, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Non-Small Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Allergic Asthma, Atopic Dermatitis (Atopic Eczema), Autoimmune Disorders, Breast Cancer, Cervical Cancer, Colorectal Cancer, Epithelial Tumor, Esophageal Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Metastatic Breast Cancer, Mycosis Fungoides, Nasopharyngeal Cancer, Non-Hodgkin Lymphoma, Ovarian Cancer, Renal Cell Carcinoma, Sezary Syndrome, Spinal Cord Disorders, T-Cell Leukemia, Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Tropical Spastic Paraparesis.
The latest report C-C Chemokine Receptor Type 4 - Pipeline Review, H2 2018, outlays comprehensive information on the C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C-C Chemokine Receptor Type 4 (K5-5 or CD194 or CCR4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.